Human gene essentiality

Nature Reviews Genetics

Volumn 19, Issue 1, 2018, Pages 51-62

  Bartha, István ^a   Di Iulio, Julia ^a   Venter, J Craig ^a,b   Telenti, Amalio ^a,b  

^a Human Longevity Inc   (United States)

^b J CRAIG VENTER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; UNTRANSLATED RNA;

ALLELE; ARTICLE; CELL LINE; CELL VIABILITY; DRUG DESIGN; ESSENTIAL GENE; EXOME; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMAN; HUMAN GENOME; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LOSS OF FUNCTION MUTATION; MEDICAL GENETICS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENETIC VARIATION; GENETICS; GENOMICS; MOUSE;

ANIMALS; GENES, ESSENTIAL; GENETIC VARIATION; GENOME, HUMAN; GENOMICS; HAPLOINSUFFICIENCY; HUMANS; MICE; MICE, KNOCKOUT; RNA, UNTRANSLATED;

EID: 85039852688     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg.2017.75     Document Type: Article

References (86)

1. Maniloff, J. The minimal cell genome: “on being the right size”. Proc. Natl Acad. Sci. USA 93, 10004–10006 (1996).
2. Hutchison, C. A., III, et al. Global transposon mutagenesis and a minimal Mycoplasma genome. Science 286, 2165–2169 (1999).
3. Hutchison, C. A., III, et al. Design and synthesis of a minimal bacterial genome. Science 351, aad6253 (2016).
4. Liu, G. et al. Gene essentiality is a quantitative property linked to cellular evolvability. Cell 163, 1388–1399 (2015).
5. Luo, H., Lin, Y., Gao, F., Zhang, C. T. & Zhang, R. DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res. 42, D574–D580 (2014).
6. Deutschbauer, A. M. et al. Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast. Genetics 169, 1915–1925 (2005).
7. Cirulli, E. T. et al. A whole-genome analysis of premature termination codons. Genomics 98, 337–342 (2011).
8. Rausell, A. et al. Analysis of stop-gain and frameshift variants in human innate immunity genes. PLoS Comput. Biol. 10, e1003757 (2014).
9. Rivas, M. A. et al. Human genomics. Effect of predicted protein-truncating genetic variants on the human transcriptome. Science 348, 666–669 (2015).
10. MacArthur, D. G. et al. A systematic survey of loss of function variants in human protein-coding genes. Science 335, 823–828 (2012).
11. Lappalainen, T. et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501, 506–511 (2013).
12. Montgomery, S. B., Lappalainen, T., GutierrezArcelus, M. & Dermitzakis, E. T. Rare and common regulatory variation in population-scale sequenced human genomes. PLoS Genet. 7, e1002144 (2011).
13. Huang, N., Lee, I., Marcotte, E. M. & Hurles, M. E. Characterising and predicting haploinsufficiency in the human genome. PLoS Genet. 6, e1001154 (2010).
14. Telenti, A. et al. Deep sequencing of 10,000 human genomes. Proc. Natl Acad. Sci. USA 113, 11901–11906 (2016).
15. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
16. Dewey, F. E. et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science 354, aaf6814(2016).
17. Chamary, J. V., Parmley, J. L. & Hurst, L. D. Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat. Rev. Genet. 7, 98–108 (2006).
18. Hunt, R. C., Simhadri, V. L., Iandoli, M., Sauna, Z. E. & Kimchi-Sarfaty, C. Exposing synonymous mutations. Trends Genet. 30, 308–321 (2014).
19. Petrovski, S., Wang, Q., Heinzen, E. L., Allen, A. S. & Goldstein, D. B. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 9, e1003709 (2013).
20. Rackham, O. J., Shihab, H. A., Johnson, M. R. & Petretto, E. EvoTol: a protein-sequence based evolutionary intolerance framework for disease-gene prioritization. Nucleic Acids Res. 43, e33 (2015).
21. Samocha, K. E. et al. A framework for the interpretation of de novo mutation in human disease. Nat. Genet. 46, 944–950 (2014).
22. Fadista, J., Oskolkov, N., Hansson, O. & Groop, L. LoFtool: a gene intolerance score based on loss of function variants in 60 706 individuals. Bioinformatics 33, 471–474 (2016).
23. Bartha, I. et al. The characteristics of heterozygous protein truncating variants in the human genome. PLoS Comput Biol 11, e1004647 (2015).
24. Cassa, C. A. et al. Estimating the selective effects of heterozygous protein-truncating variants from human exome data. Nat. Genet. 49, 806–810 (2017).
25. Dang, V. T., Kassahn, K. S., Marcos, A. E. & Ragan, M. A. Identification of human haploinsufficient genes and their genomic proximity to segmental duplications. Eur. J. Hum. Genet. 16, 1350–1357 (2008).
26. Khurana, E., Fu, Y., Chen, J. & Gerstein, M. Interpretation of genomic variants using a unified biological network approach. PLoS Comput. Biol. 9, e1002886 (2013).
27. Steinberg, J., Honti, F., Meader, S. & Webber, C. Haploinsufficiency predictions without study bias. Nucleic Acids Res. 43, e101 (2015).
28. Shihab, H. A., Rogers, M. F., Campbell, C. & Gaunt, T. R. HIPred: an integrative approach to predicting haploinsufficient genes. Bioinformatics 33, 1751–1757 (2017).
29. Giaever, G. & Nislow, C. The yeast deletion collection: a decade of functional genomics. Genetics 197, 451–465 (2014).
30. Fraser, A. Essential Human Genes. Cell Syst. 1, 381–382 (2015).
31. Dickerson, J. E., Zhu, A., Robertson, D. L. & Hentges, K. E. Defining the role of essential genes in human disease. PLoS ONE 6, e27368 (2011).
32. Khuri, S. & Wuchty, S. Essentiality and centrality in protein interaction networks revisited. BMC Bioinformatics 16, 109 (2015).
33. Vinayagam, A. et al. Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets. Proc. Natl Acad. Sci. USA 113, 4976–4981 (2016).
34. Georgi, B., Voight, B. F. & Bucan, M. From mouse to human: evolutionary genomics analysis of human orthologs of essential genes. PLoS Genet. 9, e1003484 (2013).
35. Cannavo, E. et al. Genetic variants regulating expression levels and isoform diversity during embryogenesis. Nature 541, 402–406 (2017).
36. Jeong, H., Mason, S. P., Barabasi, A. L. & Oltvai, Z. N. Lethality and centrality in protein networks. Nature 411, 41–42 (2001).
37. Zhang, X., Acencio, M. L. & Lemke, N. Predicting essential genes and proteins based on machine learning and network topological features: a comprehensive review. Front. Physiol. 7, 75 (2016).
38. Blomen, V. A. et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092–1096 (2015).
39. Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515–1526 (2015).
40. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR Cas9 system. Science 343, 80–84 (2014).
41. Rosenthal, N. & Brown, S. The mouse ascending: perspectives for human-disease models. Nat. Cell Biol. 9, 993–999 (2007).
42. Ayadi, A. et al. Mouse large-scale phenotyping initiatives: overview of the European Mouse Disease Clinic (EUMODIC) and of the Wellcome Trust Sanger Institute Mouse Genetics Project. Mamm. Genome 23, 600–610 (2012).
43. Justice, M. J. & Dhillon, P. Using the mouse to model human disease: increasing validity and reproducibility. Dis. Model. Mech. 9, 101–103 (2016).
44. Prado, A., Canal, I. & Ferrus, A. The haplolethal region at the 16F gene cluster of Drosophila melanogaster: structure and function. Genetics 151, 163–175 (1999).
45. Howell, G. R., Munroe, R. J. & Schimenti, J. C. Transgenic rescue of the mouse t complex haplolethal locus Thl1. Mamm. Genome 16, 838–846 (2005).
46. Dickinson, M. E. et al. High-throughput discovery of novel developmental phenotypes. Nature 537, 508–514 (2016).
47. Dey, G., Jaimovich, A., Collins, S. R., Seki, A. & Meyer, T. Systematic discovery of human gene function and principles of modular organization through phylogenetic profiling. Cell Rep. http://dx.doi.org/10.1016/j.celrep.2015.01.025 (2015).
48. Edwards, A. M. et al. Too many roads not taken. Nature 470, 163–165 (2011).
49. Ganna, A. et al. Quantifying the impact of rare and ultra-rare coding variation across the phenotypic spectrum. Preprint at http://biorxiv.org/content/early/2017/06/09/148247 (2017).
50. Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980–D985 (2014).
51. Stenson, P. D. et al. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum. Genet. 133, 1–9 (2014).
52. Gudbjartsson, D. F. et al. Large-scale whole-genome sequencing of the Icelandic population. Nat. Genet. 47, 435–444 (2015).
53. Narasimhan, V. M., Xue, Y. & Tyler-Smith, C. Human knockout carriers: dead, diseased, healthy, or improved? Trends Mol. Med. 22, 341–351 (2016).
54. Narasimhan, V. M. et al. Health and population effects of rare gene knockouts in adult humans with related parents. Science 352, 474–477 (2016).
55. Sulem, P. et al. Identification of a large set of rare complete human knockouts. Nat. Genet. 47, 448–452 (2015).
56. Lim, E. T. et al. Distribution and medical impact of loss of function variants in the Finnish founder population. PLoS Genet. 10, e1004494 (2014).
57. Saleheen, D. et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature 544, 235–239 (2017).
58. Nagy, E. & Maquat, L. E. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23, 198–199 (1998).
59. Lykke-Andersen, S. & Jensen, T. H. Nonsensemediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat. Rev. Mol. Cell Biol. 16, 665–677 (2015).
60. Zhang, F. & Lupski, J. R. Non-coding genetic variants in human disease. Hum. Mol. Genet. 24, R102–R110 (2015).
61. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861–874 (2011).
62. Makrythanasis, P. & Antonarakis, S. E. Pathogenic variants in non-protein-coding sequences. Clin. Genet. 84, 422–428 (2013).
63. Gordon, C. T. & Lyonnet, S. Enhancer mutations and phenotype modularity. Nat. Genet. 46, 3–4 (2014).
64. Smedley, D. et al. A whole-genome analysis framework for effective identification of pathogenic regulatory variants in mendelian disease. Am. J. Hum. Genet. 99, 595–606 (2016).
65. Harmston, N., Baresic, A. & Lenhard, B. The mystery of extreme non-coding conservation. Phil. Trans. R. Soc. B 368, 20130021 (2013).
66. Wright, J. B. & Sanjana, N. E. CRISPR screens to discover functional noncoding elements. Trends Genet. 32, 526–529 (2016).
67. Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
68. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310–315 (2014).
69. Zhou, J. & Troyanskaya, O. G. Predicting effects of noncoding variants with deep learning-based sequence model. Nat. Methods 12, 931–934 (2015).
70. Ionita-Laza, I., McCallum, K., Xu, B. & Buxbaum, J. D. A spectral approach integrating functional genomic annotations for coding and noncoding variants. Nat. Genet. 48, 214–220 (2016).
71. Khurana, E. et al. Role of non-coding sequence variants in cancer. Nat. Rev. Genet. 17, 93–108 (2016).
72. Aggarwala, V. & Voight, B. F. An expanded sequence context model broadly explains variability in polymorphism levels across the human genome. Nat. Genet. 48, 349–355 (2016).
73. di Iulio, J. et al. The human non-coding genome defined by genetic diversity. Nat. Genet. (in the press) (2017).
74. Fulco, C. P. et al. Systematic mapping of functional enhancer-promoter connections with CRISPR interference. Science 354, 769–773 (2016).
75. Korkmaz, G. et al. Functional genetic screens for enhancer elements in the human genome using CRISPR Cas9. Nat. Biotechnol. 34, 192–198 (2016).
76. Sanjana, N. E. et al. High-resolution interrogation of functional elements in the noncoding genome. Science 353, 1545–1549 (2016).
77. Zhu, S. et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR Cas9 library. Nat. Biotechnol. 34, 1279–1286 (2016).
78. Kathiresan, S. Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J. Am. Coll. Cardiol. 65, 1562–1566 (2015).
79. Este, J. A. & Telenti, A. HIV entry inhibitors. Lancet 370, 81–88 (2007).
80. Kuehn, H. S. et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345, 1623–1627 (2014).
81. Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).
82. Samocha, K. E. et al. Regional missense constraint improves variant deleteriousness prediction. Preprint at http://biorxiv.org/content/early/2017/06/12/148353 (2017).
83. Sohail, M. et al. Negative selection in humans and fruit flies involves synergistic epistasis. Science 356, 539–542 (2017).
84. Lindblad-Toh, K. et al. A high-resolution map of human evolutionary constraint using 29 mammals. Nature 478, 476–482 (2011).
85. Kellis, M. et al. Defining functional DNA elements in the human genome. Proc. Natl Acad. Sci. USA 111, 6131–6138 (2014).
86. Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096–1101 (2015).